Hualan Biological Engineering Inc.
002007
Helyezés a részvények között
#4386
Hualan Biological Engineering Inc. operates as a biopharmaceutical company,... Hualan Biological Engineering Inc. operates as a biopharmaceutical company, specializing in the research, development, production, and commercialization of a diverse portfolio of medical products within the People's Republic of China. Its offerings span plasma-derived therapies, various viral and bacterial vaccines, recombinant proteins, and other advanced biologics. The company's extensive range of plasma products includes essential components like human albumin, a broad spectrum of human immunoglobulins (such as intravenous, rabies, hepatitis B, and tetanus formulations), and vital coagulation factors like human prothrombin complex and factor VIII. Hualan also provides specialized solutions such as lyophilized human thrombin for external use and surgical fibrin glue. In its vaccine division, Hualan offers critical immunizations, including several influenza vaccines (e.g., split virus, A H1N1, and quadrivalent forms), recombinant hepatitis B vaccine, and ACYW135 meningococcal polysaccharide vaccine. The company actively pursues strategic collaborations with key scientific organizations, most notably the Chinese Academy of Sciences, as well as other esteemed research institutes and enterprises. Established in 1992, Hualan Biological Engineering Inc. is headquartered in Xinxiang, People's Republic of China.
Részvényárfolyam
$1.92
Piaci kapitalizáció
$3.50B
Változás (1 nap)
-1.39%
Változás (1 év)
-19.45%
Ország
CN
Kereskedés Hualan Biological Engineering Inc. (002007)
Kategória
Healthcare
Hualan Biological Engineering Inc. (002007) P/S aránya
P/S arány ekkor: October 2026 TTM: 5.36
Hualan Biological Engineering Inc. legfrissebb pénzügyi jelentései és részvényára alapján a vállalat jelenlegi árbevétel aránya (P/S, TTM) 5.36. 2024 végén ez az arány 7.02 volt.
P/S arány története a(z) Hualan Biological Engineering Inc. esetén 2001 és 2026 között
P/S arány az év végén
| Év | P/S arány | Változtassa meg |
|---|---|---|
| 2026 (TTM) | 5.36 | -11.26% |
| 2025 | 6.04 | -14.05% |
| 2024 | 7.02 | -7.05% |
| 2023 | 7.56 | -17.31% |
| 2022 | 9.14 | -23.59% |
| 2021 | 11.96 | -21.76% |
| 2020 | 15.29 | 15.15% |
| 2019 | 13.28 | 53.61% |
| 2018 | 8.64 | -21.68% |
| 2017 | 11.04 | -35.77% |
| 2016 | 17.18 | -1.12% |
| 2015 | 17.38 | 11.70% |
| 2014 | 15.56 | 4.91% |
| 2013 | 14.83 | 19.00% |
| 2012 | 12.46 | -18.28% |
| 2011 | 15.25 | -31.02% |
| 2010 | 22.10 | 35.18% |
| 2009 | 16.35 | -8.44% |
| 2008 | 17.86 | -46.00% |
| 2007 | 33.07 | 232.46% |
| 2006 | 9.95 | 356.58% |
| 2005 | 2.18 | 14.63% |
| 2004 | 1.90 | -24.46% |
| 2003 | 2.52 | -31.73% |
| 2002 | 3.69 | -27.97% |
| 2001 | 5.12 | 0.00% |
P/S arány hasonló vállalatoknál vagy versenytársaknál
| Vállalat | P/S arány | P/S arány különbség | Ország |
|---|---|---|---|
| 10.02 | 86.99% |
US
|
|
| 41.70 | 678.04% |
US
|
|
| 4.19 | -21.81% |
AU
|
|
| 10.44 | 94.84% |
NL
|
|
| 4.52 | -15.70% |
BE
|
